Cardinal Health is projected to report Q3 2026 revenue of $62.4 billion and earnings per share of $2.81, with the current stock price of $204.95 trading below the average analyst target of $244.33. Investors are primarily focused on the profit margin of the Pharmaceutical and Specialty Solutions segment, which analysts estimate will grow to $766.85 million.
Performance has been bolstered by significant demand for GLP-1 medications and the expansion of the specialty business, which is on track to exceed $50 billion in annual revenue for fiscal 2026. Additionally, the ongoing turnaround and supply chain stabilization of the Global Medical Products and Distribution segment remains a critical factor for long-term investor sentiment.